Viatris Inc. (Nasdaq: VTRS) has agreed to acquire Pacira BioSciences, Inc. (Nasdaq: PCRX) for $36.50 per share in cash, an aggregate equity value of approximately $1.65Bn. The transaction is structured as an all-cash tender offer followed by a second-step merger on the same terms, and both boards have approved it unanimously. Pacira’s board unanimously recommended that stockholders tender their shares, and the companies expect the deal to close by the end of 2026. Viatris intends to fund the purchase primarily from excess cash, with the remainder drawn from short-term borrowings.

For an acquirer that spent its first years as a generics-weighted consolidator, the logic here appears to be less about scale than about mix. Pacira brings two marketed, patent-protected injectables into a portfolio Viatris has been steering toward branded and innovative medicines, and it does so with revenue and EBITDA already in hand rather than in a pipeline. The price looks like a control premium for a commercial asset rather than a development bet, which is a meaningful distinction in how the market is likely to read it.

Transaction Overview

Pacira closed at $25.20 on October 7, 2026, the session before the announcement, which puts the $36.50 offer at a premium of approximately 45.0%. That figure is calculated from the disclosed price and the prior close, and it should be treated as approximate. For the twelve months to June 30, 2026, Pacira reported approximately $746.0MM in total revenue and approximately $177.0MM in adjusted EBITDA. On those inputs, the $1.65Bn equity value implies roughly 2.2x trailing revenue and roughly 9x trailing adjusted EBITDA, before any adjustment for Pacira’s net debt, which would raise the enterprise-value multiple.

The conditions are narrow. Closing requires a majority of Pacira’s outstanding shares to be tendered and the applicable regulatory waiting period to expire, and the offer carries no financing condition. Pacira’s common stock would cease trading on the Nasdaq Global Select Market once the merger is completed. A tender-offer structure of this kind typically moves faster than a one-step merger requiring a stockholder vote, which is consistent with the stated year-end timetable.

Strategic Rationale and the Non-Opioid Pain Franchise

Pacira’s EXPAREL, a bupivacaine liposome injectable suspension, is indicated for postsurgical analgesia, and ZILRETTA, a triamcinolone acetonide extended-release injectable suspension, is indicated for osteoarthritis pain of the knee. Both are administered in procedural settings, which means they reach prescribers through hospital and ambulatory surgery channels rather than through retail pharmacy. Viatris has framed the acquisition as establishing a leading position in non-opioid pain management, and it has linked the two products to its own fast-acting meloxicam opportunity. The combination suggests an attempt to assemble a pain franchise spanning the perioperative episode rather than a single product line.

The commercial reasoning is probably straightforward. A company with a meloxicam program needs a sales organization calling on surgeons and anesthesiologists, and acquiring one that is already built and already generating revenue is usually faster than constructing it. Viatris has not quantified synergies or an earnings contribution, saying only that it expects the transaction to be immediately accretive to its financial guidance metrics. The absence of a synergy figure may indicate that the case rests more on revenue and channel leverage than on cost removal, though that reading is based on inference rather than disclosure.

Financing and Balance Sheet Positioning

Funding the purchase primarily from excess cash is the detail most likely to matter to Viatris holders. Management expects minimal impact on the gross leverage ratio, which would leave the company’s deleveraging path broadly intact while adding a cash-generative asset. For an acquirer that has carried substantial leverage since its formation, paying for a $1.65Bn acquisition without a significant debt raise is a different signal than funding it in the bond market.

The structure also appears to reduce execution risk. An offer that does not depend on syndication or on a financing condition is less exposed to credit-market conditions between signing and closing, and that likely narrows the range of outcomes for holders trading the spread. Pacira’s trailing adjusted EBITDA of approximately $177.0MM provides immediate coverage against the cash outlay, and the accretion claim is consistent with that arithmetic even without a disclosed figure. Whether the asset holds its margin profile under Viatris ownership is the open question, and nothing in the announcement addresses that question directly.

Broader Implications for Pharmaceuticals M&A

The transaction fits a pattern that has been visible across specialty pharmaceuticals through 2026. Acquirers have shown a clear preference for commercial-stage assets with approved products, established reimbursement and measurable revenue, rather than for clinical-stage platforms requiring years of further spend. Pacira is close to that template: two approved injectables, a defined prescriber base and trailing EBITDA that can be underwritten. Assets with those characteristics have tended to attract competitive interest, and that may partly explain a premium near 45.0% for a business of this size.

Non-opioid analgesia is also a category in which clinical practice and payer behavior appear to point in the same direction. Prescribing guidelines and reimbursement policy in the U.S. have moved steadily against opioid analgesics for routine postsurgical use, and that likely supports volume for products positioned as alternatives. A generics-rooted acquirer buying into the category suggests the shift is now being treated as a durable commercial opportunity rather than a temporary regulatory artifact. Mid-cap specialty companies holding single-category franchises may find themselves assessed on a similar basis.

Conclusion

The acquisition appears to be a mix-improving purchase executed with balance sheet capacity rather than with new leverage. Viatris is paying approximately $1.65Bn, mostly from cash on hand, for two marketed injectables that would give it a distribution footprint in procedural pain and a complement to its own meloxicam program. The conditions are limited, the timetable is short and the consideration is cash, which together make the closing risk look modest relative to many transactions of comparable size.

What remains to be demonstrated is whether the assembled pain franchise performs better than its parts. Viatris has described the deal as immediately accretive to its guidance metrics without quantifying that claim, so holders will be judging it against reported results rather than against a disclosed model. On the evidence available, the transaction looks like a disciplined step in a strategy Viatris has already stated, priced at a premium that the asset’s revenue and EBITDA appear to support.

About DelMorgan & Co. (www.delmorganco.com)

With over $300 billion of successful transactions in over 80 countries, DelMorgan’s Investment Banking professionals have worked on some of the most challenging, most rewarding and highest profile transactions in the U.S. and around the globe. DelMorgan specializes in capital raising and M&A advisor services for companies across all industries and is recognized as one of the leading investment banking practices in California and globally.

Learn more about DelMorgan’s Capabilities, Transactions, and why DelMorgan is ranked as the #1 Investment Bank in Los Angeles and #2 in California by Axial.